Results 131 to 140 of about 1,201,269 (362)

Adjuvant chemotherapy [PDF]

Cancer, 1965
Steven G. Economou, Gerald O. McDonald, Warren H. Cole, Francis W. Strehl, Rudolph G. Mrazek, Danely P. Slaughter M.D. and   +5 more
openaire   +3 more sources

Integrative Multi‐Omics and Routine Blood Analysis Using Deep Learning: Cost‐Effective Early Prediction of Chronic Disease Risks

Advanced Science, EarlyView.
Omicsformer, a deep learning model, integrates multi‐omics and routine blood data to accurately predict risks for nine chronic diseases, including cancer and cardiovascular conditions. Validated using large scale clinical data, it reveals early risk trajectories, advancing personalized medicine and offering a cost‐effective, community‐based solution ...
Zhibin Dong, Pei Li, Yi Jiang, Zhihan Wang, Shihui Fu, Hebin Che, Meng Liu, Xiaojing Zhao, Chunlei Liu, Chenghui Zhao, Qin Zhong, Chongyou Rao, Siwei Wang, Suyuan Liu, Dayu Hu, Dongjin Wang, Juntao Gao, Kai Guo, Xinwang Liu, En Zhu, Kunlun He   +20 more
wiley   +1 more source

Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer

Cancer, 2016
The role of adjuvant chemotherapy in patients with stage II colon cancer remains to be elucidated and its use varies between patients and institutions.
L. Casadaban, G. Rauscher, M. Aklilu, Dana Villenes, S. Freels, A. Maker   +5 more
semanticscholar   +1 more source

Verteporfin‐Mediated In Situ Nanovaccine Based on Local Conventional‐Dose Hypofractionated Radiotherapy Enhances Antitumor and Immunomodulatory Effect

Advanced Science, EarlyView.
Here gelatinase‐responsive methoxypolyethyleneglycol–PVGLIG–polycaprolactone (mPEG–PVGLIG–PCL) nanoparticles’ loading verteporfin (N@VP) is developed, enhancing radiotherapy via X‐ray‐triggered singlet oxygen generation. Combined with 2 Gy (gray, a radiation dose unit) irradiation, N@VP achieves antitumor efficacy comparable to 8 Gy, and also promotes ...
Zhifan Zhang, Lin Li, Yuchen Ge, Anni Chen, Shanchao Diao, Yueling Yang, Qianyue Chen, Yingling Zhou, Jie Shao, Fanyan Meng, Lixia Yu, Manman Tian, Xiaoping Qian, Zhaoyu Lin, Chen Xie, Baorui Liu, Rutian Li   +16 more
wiley   +1 more source

Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial

JAMA Surgery, 2017
Importance Locoregional failure for patients with locally advanced bladder cancer (LABC) after radical cystectomy (RC) is common even with chemotherapy and is associated with high morbidity and mortality.
M. Zaghloul, J. Christodouleas, Andrew D. Smith, A. Abdallah, H. William, H. Khaled, W. Hwang, B. Baumann   +7 more
semanticscholar   +1 more source

Tumor‐Adhesive Chitosan‐Derived Multi‐Immune Agonist Unleashes Strong and Durable Anti‐Cancer Immunity

Advanced Science, EarlyView.
A tumor‐adhesive chitosan‐derived immune agonist TACTIC is developed for strong and durable anti‐tumor immunity. The immune agonist exhibits multi‐targets and modulates both tumor cell immunogenicity and pro‐inflammatory responses in immune cells, thereby potentiating the therapeutic efficacy of clinical radiotherapy.
Huilan He, Liang Liu, Yun Zheng, Jinlong Ji, Li Cao, Chunlian Ye, Yu Sun, Ying Zhang, Zhiyuan Zhong   +8 more
wiley   +1 more source

Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000–2013

Annals of Oncology, 2017
Background We sought to evaluate the impact of adjuvant chemotherapy on overall survival (OS) in patients with stage I endometrioid epithelial ovarian cancer (EEOC) or ovarian clear cell cancer (OCCC) using a national database. Patients and methods The
A. Oseledchyk, M. Leitao, M. Leitao, J. Konner, J. Konner, R. O'Cearbhaill, R. O'Cearbhaill, D. Zamarin, D. Zamarin, Y. Sonoda, Y. Sonoda, G. Gardner, G. Gardner, K. Roche, K. Roche, C. Aghajanian, C. Aghajanian, R. Grisham, R. Grisham, C. Brown, C. Brown, A. Snyder, A. Snyder, D. Chi, D. Chi, R. Soslow, N. Abu-Rustum, N. Abu-Rustum, O. Zivanovic, O. Zivanovic   +29 more
semanticscholar   +1 more source

Reprogramming the Tumor Immune Microenvironment with ICAM‐1‐Targeted Antibody‒Drug Conjugates and B7‐H3‐CD3 Bispecific Antibodies

Advanced Science, EarlyView.
Reprogramming the tumor immune microenvironment is crucial for transforming immune “cold” tumors into “hot” inflammatory tumors. The investigation reveals that the combination of ICAM‐1‐Dxd with B7‐H3‐CD3 bispecific antibodies not only demonstrates significant inhibitory effects on tumor growth and metastasis but also plays a vital role in ...
Shoubing Zhou, Mengyu Hong, Dan Zhao, Wenyu Li, Xiaolong Yuan, Yinghong Wang, Hualong Li, Yang Yang, Tengchuan Jin, Jing Pan   +9 more
wiley   +1 more source

Adjuvant chemotherapy for rectal cancer with complete pathological response (pCR) may not be necessary: a pooled analysis of 5491 patients

Cancer Cell International, 2019
Background It is recommended postoperative adjuvant chemotherapy for all rectal cancers undergoing neo-chemoradiotherapy regardless of the final yield pathology.
Xiang Hu, Ya-Qi Li, Xiao-ji Ma, Long Zhang, San-Jun Cai, Jun-Jie Peng   +5 more
doaj   +1 more source

Poor compliance with adjuvant chemotherapy use associated with poorer survival in patients with rectal cancer: An NCDB analysis

Cancer, 2017
National Comprehensive Cancer Network treatment guidelines for patients with locally advanced rectal cancer include neoadjuvant chemoradiation followed by total mesorectal excision and adjuvant chemotherapy.
Zhaomin Xu, S. Mohile, M. Tejani, A. Becerra, Christian P Probst, C. Aquina, Bradley J. Hensley, Reza Arsalanizadeh, K. Noyes, J. Monson, F. Fleming   +10 more
semanticscholar   +1 more source